Cargando…

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers

Evogliptin (EV) is a novel dipeptidyl peptidase‐4 inhibitor (DPP4i) for glycemic control in patients with type 2 diabetes mellitus (T2DM). This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between EV and sodium glucose cotransporter‐2 inhibitors (SGLT2i) in healthy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Dasohm, Choi, Minkyu, Jin, Byung Hak, Hong, Taegon, Kim, Choon Ok, Yoo, Byung Won, Park, Min Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432875/ https://www.ncbi.nlm.nih.gov/pubmed/37282359 http://dx.doi.org/10.1111/cts.13566

Ejemplares similares

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
por: Kim, Heeyoung, et al.
Publicado: (2023)

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
por: Kim, Dasohm, et al.
Publicado: (2019)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers
por: Park, Jungsin, et al.
Publicado: (2017)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
por: Hwang, Inyoung, et al.
Publicado: (2020)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
por: Gu, Namyi, et al.
Publicado: (2014)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
por: Lee, Jieon, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
por: Hall, Jesse, et al.
Publicado: (2018)

In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations
por: Jeong, Hyeon-Uk, et al.
Publicado: (2015)

Improved Manufacturability and In Vivo Comparative Pharmacokinetics of Dapagliflozin Cocrystals in Beagle Dogs and Human Volunteers
por: Cho, Sangho, et al.
Publicado: (2021)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers
por: Tacca, Mario Del, et al.
Publicado: (2013)

A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519
por: Kim, Choon Ok, et al.
Publicado: (2020)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Comparison of pharmacokinetics and safety of fixed-dose combination of SKI306X and aceclofenac versus separate tablets in healthy subjects
por: Meng, Xue, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications
por: Sun, Lei, et al.
Publicado: (2023)

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers
por: Gillen, Michael, et al.
Publicado: (2016)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
por: Peterschmitt, M. Judith, et al.
Publicado: (2020)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers
por: Wu, Kai, et al.
Publicado: (2016)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice
por: Kim, Jin Hyun, et al.
Publicado: (2020)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
por: Hong, Taegon, et al.
Publicado: (2015)

Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
por: Yang, Ai-Yu, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic drug-drug interaction of Nomilin with atorvastatin in hyperlipidemic mice
por: Ding, Yan, et al.
Publicado: (2023)

The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain
por: Cho, Pyung Goo, et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
por: Kim, Choon Ok, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats
por: Bergh, Marianne Skov-Skov, et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2013)

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
por: Shin, Wonsuk, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uc4troj6gd5vbbu3nhnuqgh5gc